Matches in SemOpenAlex for { <https://semopenalex.org/work/W1886543296> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W1886543296 abstract "17548 Background: CHOP combination chemotherapy is the most effective and least toxic regimen for high-grade Non-Hodgkin’s-lymphoma (NHL). Doxorubicin, however, presents a problem in patients at risk for cardiotoxicity. Pegliposomal doxorubicin is a liposomal preparation of doxorubicin with minimal cardiotoxicity. In the CLAOP regimen reported here, we substituted conventional doxorubicin in the CHOP regimen by pegliposomal doxorubicin. Methods: An open-label phase I/IIa study was performed evaluating CLAOP21/20 with 20 mg/m 2 of pegliposomal doxorubicin every 21 days, and a dose-dense CLAOP14 regimen supported by G-CSF or pegylated G-CSF every 14 days with escalating doses of pegliposomal doxorubicin in elderly high-grade lymphoma patients. Results: A total of 12 patients were enrolled for CLAOP 21/20, and 24 patients for CLAOP 14/20. CLAOP21/20 was well tolerated with a degree of hematotoxicity similar to that reported with regular CHOP. In the CLAOP14 cohort, a trend towards cumulative hematotoxicity. Palmar plantar erythema (PPE) exceeding grade II and other non-hematological toxicities exceeding grade I, except of alopecia, were not observed. A pegliposomal doxorubicin dose of 25 mg/m 2 (CLAOP14/25) was associated with dose-limiting haematotoxicity, febrile episodes, and PPE. Both, the 3-weekly and the 2-weekly regimens were active with an overall response rate of 60% and 77%, respectively. Cardiotoxicity attributable to doxorubicin was not observed in any patient. Conclusions: The recommended dose of pegliposomal doxorubicin in the biweekly CLAOP regimen for Phase II/III testing is 20 mg/m 2 , a regimen that can safely be administered to old patients without apparent cardiotoxicity. [Table: see text]" @default.
- W1886543296 created "2016-06-24" @default.
- W1886543296 creator A5046413239 @default.
- W1886543296 creator A5066640097 @default.
- W1886543296 creator A5086382362 @default.
- W1886543296 creator A5087897938 @default.
- W1886543296 creator A5089816329 @default.
- W1886543296 date "2006-06-20" @default.
- W1886543296 modified "2023-10-14" @default.
- W1886543296 title "A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma and cardiac risk factors" @default.
- W1886543296 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.17548" @default.
- W1886543296 hasPublicationYear "2006" @default.
- W1886543296 type Work @default.
- W1886543296 sameAs 1886543296 @default.
- W1886543296 citedByCount "0" @default.
- W1886543296 crossrefType "journal-article" @default.
- W1886543296 hasAuthorship W1886543296A5046413239 @default.
- W1886543296 hasAuthorship W1886543296A5066640097 @default.
- W1886543296 hasAuthorship W1886543296A5086382362 @default.
- W1886543296 hasAuthorship W1886543296A5087897938 @default.
- W1886543296 hasAuthorship W1886543296A5089816329 @default.
- W1886543296 hasConcept C126322002 @default.
- W1886543296 hasConcept C143998085 @default.
- W1886543296 hasConcept C2776694085 @default.
- W1886543296 hasConcept C2778233292 @default.
- W1886543296 hasConcept C2779338263 @default.
- W1886543296 hasConcept C2779725641 @default.
- W1886543296 hasConcept C2781303535 @default.
- W1886543296 hasConcept C2781413609 @default.
- W1886543296 hasConcept C31760486 @default.
- W1886543296 hasConcept C71924100 @default.
- W1886543296 hasConcept C90924648 @default.
- W1886543296 hasConceptScore W1886543296C126322002 @default.
- W1886543296 hasConceptScore W1886543296C143998085 @default.
- W1886543296 hasConceptScore W1886543296C2776694085 @default.
- W1886543296 hasConceptScore W1886543296C2778233292 @default.
- W1886543296 hasConceptScore W1886543296C2779338263 @default.
- W1886543296 hasConceptScore W1886543296C2779725641 @default.
- W1886543296 hasConceptScore W1886543296C2781303535 @default.
- W1886543296 hasConceptScore W1886543296C2781413609 @default.
- W1886543296 hasConceptScore W1886543296C31760486 @default.
- W1886543296 hasConceptScore W1886543296C71924100 @default.
- W1886543296 hasConceptScore W1886543296C90924648 @default.
- W1886543296 hasLocation W18865432961 @default.
- W1886543296 hasOpenAccess W1886543296 @default.
- W1886543296 hasPrimaryLocation W18865432961 @default.
- W1886543296 hasRelatedWork W160156331 @default.
- W1886543296 hasRelatedWork W1886543296 @default.
- W1886543296 hasRelatedWork W2110443444 @default.
- W1886543296 hasRelatedWork W2341761393 @default.
- W1886543296 hasRelatedWork W2383526802 @default.
- W1886543296 hasRelatedWork W2607666181 @default.
- W1886543296 hasRelatedWork W2793680908 @default.
- W1886543296 hasRelatedWork W2807576627 @default.
- W1886543296 hasRelatedWork W2909980364 @default.
- W1886543296 hasRelatedWork W4239581391 @default.
- W1886543296 isParatext "false" @default.
- W1886543296 isRetracted "false" @default.
- W1886543296 magId "1886543296" @default.
- W1886543296 workType "article" @default.